Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Antiviral Res. 2016 Apr 6;131:19–25. doi: 10.1016/j.antiviral.2016.03.015

Figure 3. Hit compounds inhibit RSV replicon expression.

Figure 3

APC126-E cells expressing a subgenomic RSV replicon with a luciferase gene were treated with ascending doses of hit compounds for 48 hours and then assessed for total cellular luminescent signal. The selected compounds showed dose-dependent inhibition of luciferase suggesting inhibition of either replication or expression of the replicon system. Panels A, B, and C show compounds from Series 1, 2, and 3, respectively. EC50 values are provided in Table 1.